

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>E&amp;Investment, Inc.</u>  (Last) (First) (Middle) C/O NEUROBO PHARMACEUTICALS, INC. 200 BERKELEY STREET, OFFICE 19TH FLOOR  (Street) BOSTON, MA 02116  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>NeuroBo Pharmaceuticals, Inc.</u> [ NRBO ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 07/26/2022	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/26/2022		J <sup>(1)</sup>		1,445,267	D	\$0	2,890,533	I	Held by The E&Healthcare Investment Fund II <sup>(2)(3)</sup>
Common Stock								140,147 <sup>(4)</sup>	D	
Common Stock								1,121,190	I	Held by The E&Healthcare Investment Fund No. 6 <sup>(3)(5)</sup>
Common Stock								1,864,799	I	Held by The E&Healthcare Investment Fund No. 7 <sup>(3)(6)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person\*  
E&Investment, Inc.  
  
 (Last) (First) (Middle)  
 C/O NEUROBO PHARMACEUTICALS, INC.  
 200 BERKELEY STREET, OFFICE 19TH FLOOR  
  
 (Street)  
 BOSTON, MA 02116  
  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
E&Healthcare Investment Fund II

(Last)	(First)	(Middle)
C/O NEUROBO PHARMACEUTICALS, INC.		
200 BERKELEY STREET, OFFICE 19TH FLOOR		

(Street)		
BOSTON,	MA	02116

(City)	(State)	(Zip)
--------	---------	-------

**Explanation of Responses:**

1. E&Healthcare Investment Fund II distributed 1,445,267 shares to its partners on a pro rata basis, for no consideration.
2. These shares are owned directly by The E&Healthcare Investment Fund II, a 10% owner of the Issuer, and indirectly by its sole general partner, E&Investment, Inc.
3. E&Investment, Inc. disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
4. E&Investment, Inc. received a pro rata distribution from E&Healthcare Investment Fund II.
5. These shares are owned directly by The E&Healthcare Investment Fund No. 6, and indirectly by its sole general partner, E&Investment, Inc.
6. These shares are owned directly by The E&Healthcare Investment Fund No.7, and indirectly by its sole general partner, E&Investment, Inc.

/s/ E&I Investment, Inc., By: 07/28/2022  
Na Yeon Kim, CEO

/s/ The E&Healthcare  
Investment Fund II, By: Na 07/28/2022  
Yeon Kim, Representative  
Director

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**